Liraglutide
Saxenda / Victoza
Liraglutide (Saxenda / Victoza) is a metabolic & fat loss research compound. GLP-1 receptor agonist — the daily-dosed predecessor to semaglutide; appetite suppression, slowed gastric emptying, glucose-dependent insulin.
Liraglutide quick facts
| Reported research dose | 0.6mg-3mg |
| Route | Subq |
| Frequency | 1x Daily |
| Half-life | ~13 hrs |
| Forms | Injectable |
| Evidence level | FDA-approved; human |
Daily injection is the downside vs weekly options, but it's proven and titratable.
How Liraglutide works
GLP-1 receptor agonist — the daily-dosed predecessor to semaglutide; appetite suppression, slowed gastric emptying, glucose-dependent insulin.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Can you actually get Liraglutide?
Branded Saxenda/Victoza only. My partners carry semaglutide and tirzepatide instead, both of which outperform it.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Liraglutide
Graded by what exists behind each claim.
✅ Clinically validated
- FDA-approved twice — as Victoza for type 2 diabetes and as Saxenda at 3 mg for weight management, on the back of the SCALE trials, which showed roughly 8% mean weight loss at 56 weeks.
- LEADER (9,340 patients, 3.8 years) is the more important trial: it showed a significant reduction in cardiovascular death, non-fatal MI and stroke in type 2 diabetics at high CV risk. That is a hard-outcome result, not a surrogate one, and it is what separates this class from every other weight drug in history.
📊 Correlative data
- Over a decade of prescribing, so the real-world profile is well characterized: nausea early and dose-dependent, gallbladder events at a low but real rate, and loss of lean mass alongside fat unless resistance training and protein intake are deliberate.
- Daily injection is the practical reason it has largely been displaced by semaglutide and tirzepatide rather than any efficacy failure.
🧪 Theoretical / extrapolated
- A GLP-1 receptor agonist with 97% homology to native GLP-1, acylated with a fatty acid so it binds albumin and survives about 13 hours instead of minutes. It acts on three fronts: glucose-dependent insulin secretion, slowed gastric emptying, and hypothalamic appetite signaling.
- Glucose-dependence is why hypoglycemia is rare on it alone — the insulin signal switches off as glucose falls. Add a sulfonylurea or insulin and that protection disappears, which is the interaction that actually matters.
- The CV benefit appears larger than weight loss alone predicts, pointing at direct vascular GLP-1 receptor effects.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Liraglutide actually does
Native GLP-1(7-37) has a half-life of a couple of minutes. Dipeptidyl peptidase-4 cleaves the first two residues off the N-terminus — the cut is after the alanine at position 8 — and neutral endopeptidase finishes the job. Every long-acting GLP-1 agonist is an answer to that one problem, and which answer a molecule chose is what determines whether you inject it daily or weekly. Liraglutide's answer is the reason it is a daily drug.
The engineering, exactly as the label states it. The peptide backbone is 97% homologous to native human GLP-1, differing by a single substitution — arginine for lysine at position 34 — and then a C-16 fatty acid (palmitic acid) with a glutamic acid spacer is attached to the remaining lysine at position 26 US Food and Drug Administration 2025. That is the whole molecule. Note what it is not: the alanine at position 8, the actual DPP-4 cleavage site, is left alone. The Lys34→Arg swap exists only to give the acylation chemistry a single unambiguous attachment point.
So how does an unmutated cleavage site survive? By being hidden. The palmitic acid binds reversibly to albumin, and Plum 2013 measured how tightly: at a clinically relevant concentration, liraglutide is more than 98.9% bound to total plasma protein, 99.4% to human serum albumin and 99.3% to alpha-1 acid glycoprotein. Fewer than eleven molecules in a thousand are free at any instant. The peptidases can only work on the free fraction, so the effective degradation rate collapses by orders of magnitude. The label describes the same three-part mechanism: self-association that delays absorption, plasma protein binding, and stability against DPP-4 and NEP US Food and Drug Administration 2025.
Why C16 and not C18, and why that single choice is the difference between daily and weekly. A longer, more strongly albumin-binding fatty acid holds the peptide in the albumin pool longer. Semaglutide, from the same discovery program, uses a longer diacid chain with an extended spacer and substitutes the position-8 alanine outright — three changes instead of one — and gets about a week Knudsen 2019. Liraglutide's C16 palmitoyl group with a single glutamic acid spacer gets 13 hours US Food and Drug Administration 2025. The dosing frequency of these drugs is a choice about the length of a fatty acid. Nothing about the receptor differs.
What the receptor does once engaged. GLP-1 receptor activation is Gs-coupled and raises cAMP. In the beta cell that amplifies glucose-dependent insulin secretion — the amplification requires glucose to be elevated, which is why hypoglycemia is rare on this drug alone. In the stomach it slows gastric emptying. In the hypothalamus and brainstem it suppresses appetite. Pyke 2014 mapped GLP-1 receptor distribution in monkey and human tissue with an extensively validated monoclonal antibody, and the point of that work is that the receptor is present in fewer and more specific places than the earlier antibody literature claimed. Knudsen 2019 lists pancreas, gastrointestinal tract, heart, lungs, kidneys and brain. The heart entry on that list is the one that matters twice over — once for the heart rate rise, and once for LEADER.
Cell, rodent, human — and where it stops
Step one, protein chemistry. Plum 2013 established the binding fractions by reiterated stepwise equilibrium dialysis — 99.4% to albumin, 99.3% to alpha-1 acid glycoprotein — which is the measurement the whole protraction mechanism rests on.
Step two, receptor mapping in primate and human tissue. Pyke 2014 used a validated monoclonal antibody across monkey and human tissue to establish where the receptor actually is, which matters because a great deal of speculative GLP-1 biology has been built on antibodies that were not validated.
Step three, human weight loss, and the endpoint was met. SCALE Pi-Sunyer 2015 randomized 3,731 people with obesity but without type 2 diabetes, 2:1, to liraglutide 3.0 mg or placebo for 56 weeks; mean baseline weight 106.2 kg, BMI 38.3, 78.5% women, 61.2% with prediabetes. Weight loss was 8.4 ± 7.3 kg on liraglutide versus 2.8 ± 6.5 kg on placebo, a difference of −5.6 kg (95% CI −6.0 to −5.1, p < 0.001). 63.2% lost at least 5% of body weight against 27.1% on placebo, and 33.1% lost more than 10% against 10.6%. Serious adverse events 6.2% versus 5.0%.
Step four, LEADER — and this is the trial that makes liraglutide different from an appetite suppressant. Marso 2016 randomized 9,340 people with type 2 diabetes at high cardiovascular risk to liraglutide 1.8 mg or placebo for a median of 3.8 years. The primary composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 608 of 4,668 (13.0%) on liraglutide against 694 of 4,672 (14.9%) — hazard ratio 0.87 (95% CI 0.78–0.97), p < 0.001 for non-inferiority and p = 0.01 for superiority. Then the two components that matter most: cardiovascular death 4.7% versus 6.0%, HR 0.78 (0.66–0.93), p = 0.007, and all-cause mortality 8.2% versus 9.6%, HR 0.85 (0.74–0.97), p = 0.02. A drug that reduces death from any cause in a randomized trial of nine thousand people is in a different category from a drug that reduces a surrogate.
Step five, the population pharmacokinetics behind the higher dose. Overgaard 2016 built the population model for liraglutide 3.0 mg in weight management, which is what supports dosing the same molecule at nearly twice the diabetes dose.
The obstacle, and it has two halves. First, LEADER was run in people with type 2 diabetes and established cardiovascular disease or high risk — the cardiovascular result does not automatically transfer to a metabolically healthy person using liraglutide for cosmetic weight loss, because absolute risk reduction scales with baseline risk and theirs is small. Second, the weight number is the weakest in the modern class: 8.4 kg at 56 weeks Pi-Sunyer 2015, against the double-digit percentages the weekly agents report. And no trial has ever compared liraglutide with semaglutide or tirzepatide on a cardiovascular endpoint, so the question of whether the CV benefit is a class effect or a liraglutide effect is genuinely open.
Liraglutide pharmacokinetics — how much of it actually gets in
Route: subcutaneous, once daily, and the once-daily part is the whole clinical personality of this molecule. Bioavailability is approximately 55%, peak concentrations occur 8 to 12 hours after dosing, and the plasma half-life is 13 hours US Food and Drug Administration 2025. Note the shape of that: an 8–12 hour rise to peak on a 13-hour half-life produces a broad, flat curve rather than a spike, which is the self-association mechanism working — liraglutide oligomerizes at the injection site and dissolves out of that depot slowly.
What degrades it, and why nothing is recoverable. Liraglutide is endogenously metabolized in the same way as a large protein, by DPP-4 and neutral endopeptidase, with no single organ as the route of elimination US Food and Drug Administration 2025. The consequence in the mass balance is striking: intact liraglutide was not detected in urine or feces at all, with only about 6% and 5% of the dose appearing as metabolites in each. There is no renal or hepatic clearance step to adjust for, and no cytochrome interaction to worry about. Protein binding above 98.9% Plum 2013 is what keeps the peptidases away long enough for a 13-hour half-life to exist at all.
The arithmetic that argues for daily dosing, which nobody makes. A 13-hour half-life means about 95% of a dose is gone in two and a half days. A weekly agent with a half-life near a week takes five weeks. That difference is invisible while everything is going well and decisive when it is not: severe nausea, suspected pancreatitis, a planned surgery with an anesthetic aspiration concern, or a pregnancy. On liraglutide the answer to “stop and let it clear” is a weekend. It is also why titration is finer — the label's weekly steps of 0.6 → 1.2 → 1.8 mg US Food and Drug Administration 2025 land at a new steady state within two to three days of each increase, so an intolerable step can be identified and reversed quickly. The daily injection is the price of a controllable exposure, and framing it purely as a convenience disadvantage misses half the trade.
Immunogenicity, small but non-zero. 9% of liraglutide-treated patients developed anti-liraglutide antibodies and about 1% showed neutralizing activity in vitro, with no demonstrated effect on effectiveness US Food and Drug Administration 2025. That is the expected cost of a molecule that is 97% but not 100% human.
What would have to be true, and how you would know it was not
Four predictions with markers and windows. The third is a safety read-out that is routinely misread, and the fourth argues against using this particular molecule for the goal most people buy it for.
1. HbA1c and Fasting Insulin should fall, and on different timescales. Glucose-dependent insulin secretion plus weight loss plus slowed gastric emptying all push the same way. Draw both at baseline and at 12 weeks — not four, because HbA1c integrates roughly three months of glycemia and a 4-week retest measures mostly noise. Fasting insulin moves earlier than HbA1c and is the more sensitive early signal that the drug is doing metabolic work rather than only suppressing appetite.
2. ApoB should improve roughly in proportion to weight lost, and not more. Baseline and 24 weeks. This is the honest framing: most of the lipid benefit of a GLP-1 agonist is the weight loss, so ApoB falling by about what an equivalent diet-induced loss would produce is the expected result. If ApoB is unchanged despite 8 kg gone, something else is driving it — and if it improves far beyond the weight change, that is a genuinely interesting personal finding worth repeating.
3. Lipase may rise, and a raised lipase on its own is not pancreatitis. The label carries a pancreatitis warning and says to discontinue if it is suspected US Food and Drug Administration 2025. What that warning does not say — and what causes needless alarm — is that asymptomatic elevations of pancreatic enzymes are common on this class and were not accompanied by an excess of pancreatitis in LEADER, where pancreatitis was non-significantly lower on liraglutide Marso 2016. So: draw lipase at baseline so a later value has something to be compared with, and treat severe persistent abdominal pain radiating to the back, with or without vomiting as the actual stop signal — not a number.
4. The prediction that cuts against it: on weight, liraglutide should lose to the weekly agents, and by a lot. SCALE delivered a placebo-subtracted 5.6 kg at 56 weeks with 33.1% of people exceeding 10% loss Pi-Sunyer 2015. If a fair head-to-head against a weekly agent at maximum tolerated dose did not favor the weekly agent substantially, the assumption that receptor exposure duration drives weight response would be wrong. Nobody should choose liraglutide expecting to match those numbers. The defensible reasons to choose it are different ones: a hard cardiovascular outcome in its own name Marso 2016, a two-day washout, and finer titration. Add hs-CRP at baseline and 24 weeks if the cardiovascular argument is the reason for using it — the mechanism predicts it falls with weight, and a fall larger than the weight change explains would be the first personal hint of the direct vascular effect LEADER implies.
What nobody has tested yet
Nobody has tested whether the LEADER benefit belongs to the class or to this molecule. Marso 2016 showed a 22% relative reduction in cardiovascular death and a 15% reduction in all-cause mortality against placebo. No trial has compared liraglutide with a weekly GLP-1 agonist on a cardiovascular endpoint, in either direction. Given that the two differ in receptor occupancy pattern — a daily peak-and-trough against a flat weekly exposure — and that peak-versus-continuous matters enormously for other receptor systems, this is not a trivial question, and it has no data.
Nobody knows whether daily exposure protects lean mass better than weekly. The composition problem is the real cost of this class and it is measured almost nowhere. A trial of liraglutide 3.0 mg against a weekly agent at matched total weight loss, with DEXA and grip strength at 0 and 52 weeks, would answer whether the intermittent trough on a daily drug allows any recovery window that a flat weekly curve does not. Nobody has run it, and it is the question the training population actually cares about.
Nobody has measured whether the 9% antibody rate matters over years. US Food and Drug Administration 2025 reports 9% seroconversion with about 1% neutralizing in vitro and no demonstrated loss of effect — over trial-length exposure. People now take this for a decade. A cohort with antibody titers and HbA1c at years 1, 3 and 5 would settle whether the small neutralizing fraction contributes to the response loss people report over long timescales, which is currently attributed entirely to adherence and to weight regain.
And the heart-rate rise has never been explained. The label reports a mean increase of 2 to 3 beats per minute US Food and Drug Administration 2025, and Robinson 2013 pooled the trials of exenatide and liraglutide and confirmed it as a consistent class finding alongside the blood pressure and weight changes. Whether it is direct sinoatrial GLP-1 receptor activation Pyke 2014, a sympathetic reflex, or something else has not been resolved — and it is a persistent rise in a drug that otherwise reduces cardiovascular death, which is a contradiction worth solving.
Liraglutide — its own safety story, not its class's
The boxed warning is about thyroid C cells and it is a rodent finding. Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both sexes of rats and mice US Food and Drug Administration 2025. Two things follow. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — which is a question worth actually asking a family, not skipping. And it is a rodent finding whose human relevance is undetermined; rodents have far higher C-cell GLP-1 receptor density than humans do. The correct summary is that the risk is unquantified in people, not that it is zero and not that it is proven.
Gallbladder disease is the one with a real number from a real trial. In LEADER an acute gallbladder event occurred in 3.1% of liraglutide-treated patients against 1.9% on placebo US Food and Drug Administration 2025. That is a genuine excess in nine thousand people over 3.8 years, and the mechanism is not mysterious — rapid weight loss and reduced gallbladder motility both promote stone formation. Right upper quadrant pain, particularly after a fatty meal, is the presentation.
The gastrointestinal profile, at the label's rates. Nausea 20%, diarrhea 12%, vomiting 9%, decreased appetite 9% at the 1.8 mg dose US Food and Drug Administration 2025, with gastrointestinal events the leading reason for discontinuation in LEADER Marso 2016. Nearly all of it is the gastric emptying effect and nearly all of it is titration-dependent, which is where the 13-hour half-life earns its keep: an intolerable dose step washes out in about two days rather than five weeks.
Acute kidney injury, and the mechanism is dehydration. The label instructs monitoring renal function in patients with volume depletion US Food and Drug Administration 2025. Persistent vomiting and diarrhea on a drug that also suppresses thirst-driving appetite behavior is exactly how a normal kidney gets into trouble, and it is more common than any exotic mechanism.
Heart rate rises and it does not go away. Two to three beats per minute on average US Food and Drug Administration 2025 Robinson 2013. Small at the population level; worth knowing if you track resting heart rate as a recovery metric, because a persistent 3 bpm shift will otherwise be read as accumulated fatigue.
And the composition warning that belongs on every drug in this class. SCALE reported 8.4 kg of weight lost at 56 weeks Pi-Sunyer 2015 and did not report how much of it was lean tissue. Appetite suppression reduces protein intake and calorie intake together, and the muscle is lost silently. Resistance training and deliberate protein intake are not optional extras here; they are the difference between losing fat and losing weight.
Sources read for this page
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide.. Front Endocrinol 2019 · PMID 31031702
- Plum A, Jensen LB, Kristensen JB. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis.. J Pharm Sci 2013 · PMID 23853127
- Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med 2016 · PMID 27295427
- Pi-Sunyer X, Astrup A, Fujioka K. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.. N Engl J Med 2015 · PMID 26132939
- Overgaard RV, Petri KC, Jacobsen LV. Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.. Clin Pharmacokinet 2016 · PMID 27193270
- Robinson LE, Holt TA, Rees K. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.. BMJ Open 2013 · PMID 23355666
- Pyke C, Heller RS, Kirk RK. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.. Endocrinology 2014 · PMID 24467746
- US Food and Drug Administration. VICTOZA (liraglutide) injection, for subcutaneous use - full prescribing information.. FDA approved labeling, revision 2025
Liraglutide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Liraglutide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Liraglutide moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Liraglutide in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Liraglutide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | The baseline you can't reconstruct later |
| Fasting Insulin | Falls as the drug works |
| Lipase | Pancreatitis is the rare serious event worth catching early |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes during rapid intake reduction |
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 103 markers A–Z
Liraglutide — frequently asked questions
What is Liraglutide?
Liraglutide (Saxenda / Victoza) is a metabolic & fat loss research compound. GLP-1 receptor agonist — the daily-dosed predecessor to semaglutide; appetite suppression, slowed gastric emptying, glucose-dependent insulin.
Is the full Liraglutide protocol on this page?
The reported research dose is on this page, along with how Liraglutide works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Liraglutide?
Liraglutide has an approximate half-life of ~13 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Liraglutide?
Current evidence level: FDA-approved; human. Liraglutide is offered for research purposes only and is not an approved medicine.
What Liraglutide is used for
Liraglutide appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.